Captoprilis is an angiotensin-converting enzyme (ACE) inhibitor, which is known to activate ACE2 that is the receptor that SARS-CoV-2 uses to infect human cells [22], suggesting that this drug might have negative effects for COVID-19 therapy. This evidence concerns the gene ACE2 and COVID-19.